Unbalanced acetylcholinesterase activity in larynx squamous cell carcinoma

Castillo-González, Ana Cristina; Pelegrín-Hernández, Juan Pablo; Nieto, Susana; Piñero-Madrona, Antonio; Noguera, José Antonio; López-Moreno, María Fuensanta; Rodrı́guez-López, José Neptuno; Vidal, Cecilio J.; Hellín-Meseguer, Diego; Cabezas‐Herrera, Juan

doi:10.1016/j.intimp.2015.05.011

Cited by 10 publications

(8 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mutations in the ACHE gene and transcriptional regulation must be reflected in the protein synthesis and the catalytic activity. To highlight this point, Castillo-González and coworkers found that tumors with low AChE activity were associated with poorer overall survival, demonstrating that AChE activity could also indicate poor prognosis and have a relevant role during tumor development [ 86 , 87 ]. Therefore, we will focus on analyzing the levels of protein content and changes in the activity in different cancers.…”

Section: The Implication Of Acetylcholinesterase In Tumor Developmentmentioning

confidence: 99%

Changes in the Acetylcholinesterase Enzymatic Activity in Tumor Development and Progression

Pérez-Aguilar,

Marquardt,

Muñoz-Delgado

et al. 2023

Cancers

View full text Add to dashboard Cite

Acetylcholinesterase is a well-known protein because of the relevance of its enzymatic activity in the hydrolysis of acetylcholine in nerve transmission. In addition to the catalytic action, it exerts non-catalytic functions; one is associated with apoptosis, in which acetylcholinesterase could significantly impact the survival and aggressiveness observed in cancer. The participation of AChE as part of the apoptosome could explain the role in tumors, since a lower AChE content would increase cell survival due to poor apoptosome assembly. Likewise, the high Ach content caused by the reduction in enzymatic activity could induce cell survival mediated by the overactivation of acetylcholine receptors (AChR) that activate anti-apoptotic pathways. On the other hand, in tumors in which high enzymatic activity has been observed, AChE could be playing a different role in the aggressiveness of cancer; in this review, we propose that AChE could have a pro-inflammatory role, since the high enzyme content would cause a decrease in ACh, which has also been shown to have anti-inflammatory properties, as discussed in this review. In this review, we analyze the changes that the enzyme could display in different tumors and consider the different levels of regulation that the acetylcholinesterase undergoes in the control of epigenetic changes in the mRNA expression and changes in the enzymatic activity and its molecular forms. We focused on explaining the relationship between acetylcholinesterase expression and its activity in the biology of various tumors. We present up-to-date knowledge regarding this fascinating enzyme that is positioned as a remarkable target for cancer treatment.

show abstract

Section: The Implication Of Acetylcholinesterase In Tumor Developmentmentioning

confidence: 99%

Changes in the Acetylcholinesterase Enzymatic Activity in Tumor Development and Progression

Pérez-Aguilar,

Marquardt,

Muñoz-Delgado

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Nicotine and their metabolites may cause the formation of DNA adducts which result in mutations of some important cancer suppressor genes, including retinoblastoma tumor suppressor protein (Rb), tumor suppressive K-RAS protein and other GTPase enzymes as well as p53 protein and eventually contributing to tumorigenesis in various ways (Schaal & Chellappan, 2016). In another study, a comparison between cancerous and noncancerous tissue demonstrated that cancer patients exhibit altered AChE activity, which correlates with a significantly lower overall survival rate (Castillo-González et al, 2015). These findings recommended that AChE activity and cancer are correlated and the potentiation of AChE activity may be useful for improving the outcome of patients with different cancers.…”

Section: α7-mediated Signaling Pathways In Lung Cancer Regulationmentioning

confidence: 99%

Alpha7 nicotinic acetylcholine receptors in lung inflammation and carcinogenesis: Friends or foes?

Hajiasgharzadeh

Sadigh-Eteghad

Mansoori

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

The lung tissue expresses the cholinergic system including nicotinic acetylcholine receptors (nAChRs) which included in many physiologic and pathologic processes. Mounting evidence revealed that these receptors have important roles in lung carcinogenesis via modulating either stimulatory or inhibitory signaling pathways. Among different members of nicotinic receptors family, alpha7‐subtype of nAChR (α7nAChR) is a critical mediator involved in both inflammatory responses and cancers. Several studies have shown that this receptor is the most powerful regulator of responses that stimulate lung cancer processes such as proliferation, angiogenesis, metastasis, and inhibition of apoptosis. Moreover, aside from its roles in the regulation of cancer pathways, there is growing evidence indicating that α7nAChR has profound impacts on lung inflammation through the cholinergic anti‐inflammatory pathway. Regarding such diverse effects as well as the critical roles of nicotine as an activator of α7nAChR on lung cancer pathogenesis, its modulation has emerged as a promising target for drug developments. In this review, we aim to highlight the detrimental as well as the possible beneficial influences of α7nAChR downstream signaling cascades in the control of lung inflammation and cancer‐associated properties. Consequently, by considering the significant global burden of lung cancer, delineating the complex influences of α7 receptors would be of great interest in designing novel anticancer and anti‐inflammatory strategies for the patients suffering from lung cancer.

show abstract

“…M 2 /M 3 receptor subtypes have been detected in head (glioblastomas) and neck (larynx squamous) carcinomas. Almost 90% of head and neck carcinomas are assigned to squamous cell carcinoma ad it was reported that they express not only mAChRs but also the other components of the nNCS like AChE [34,35].…”

Section: The Activation Of Odd Receptors (M 1 M 3 and M 5 ) Couplesmentioning

confidence: 99%

Role of Muscarinic Acetylcholine Receptors in Breast Cancer: Design of Metronomic Chemotherapy

Sales

Español

Salem

et al. 2019

CCP

View full text Add to dashboard Cite

Background: muscarinic acetylcholine receptors (mAChRs) have attracted interest as targets for therapeutic interventions in different illnesses like Alzheimer´s disease, viral infections and different tumors. Regarding the latter, many authors have studied each subtype of mAChRs, which seem to be involved in the progression of distinct types of malignancies. Methods: We carefully revised research literature focused on mAChRs expression and signaling as well as in their involvement in cancer progression and treatment. The characteristics of screened papers were described using the mentioned conceptual framework. Results: Muscarinic antagonists and agonists have been assayed for the treatment of tumors established in lung, brain and breast with beneficial effects. We described an up-regulation of mAChRs in mammary tumors and the lack of expression in non-tumorigenic breast cells and normal mammary tissues. We and others demonstrated that muscarinic agonists can trigger anti-tumor actions in a dose-dependent manner on tumors originated in different organs like brain or breast. At pharmacological concentrations, they exert similar effects to traditional chemotherapeutic agents. Metronomic chemotherapy refers to the administration of anti-cancer drugs at low doses with short intervals among them, and it is a different regimen applied in cancer treatment reducing malignant growth and angiogenesis, and very low incidence of adverse effects. Conclusion: The usage of subthreshold concentrations of muscarinic agonists combined with conventional chemotherapeutic agents could be a promising tool for breast cancer therapy.

show abstract

Unbalanced acetylcholinesterase activity in larynx squamous cell carcinoma

Cited by 10 publications

References 35 publications

Changes in the Acetylcholinesterase Enzymatic Activity in Tumor Development and Progression

Changes in the Acetylcholinesterase Enzymatic Activity in Tumor Development and Progression

Alpha7 nicotinic acetylcholine receptors in lung inflammation and carcinogenesis: Friends or foes?

Role of Muscarinic Acetylcholine Receptors in Breast Cancer: Design of Metronomic Chemotherapy

Contact Info

Product

Resources

About